Table 3.

Details for each category of underlying diseasea

Disease typeSite or diagnosisbTotal no. of patientsNo. (%) with mycosis
Solid cancersLung15,340369 (2.4)
Stomach12,719227 (1.8)
Liver13,985167 (1.2)
Pancreas5,046100 (2.0)
Colon7,14082 (1.1)
Esophagus3,12458 (1.9)
Gall bladder3,47867 (1.9)
Breast2,27437 (1.6)
Uterus2,06840 (1.9)
Prostate3,27829 (0.9)
Ovary1,24832 (2.6)
Kidney2,11038 (1.8)
Bladder1,59041 (2.6)
Brain1,82437 (2.0)
Thyroid3,00515 (0.5)
Pharynx75220 (2.7)
Total78,9811,359 (1.7)
Blood and hematopoietic system diseasesAML1,753620 (35.4)
CML424185 (43.6)
ALL745319 (42.8)
CLL11917 (14.3)
MoL27849 (17.6)
MDS473105 (22.2)
ATL535116 (21.7)
Other leukemia1,74095 (5.5)
 Total for leukemia and MDS6,0671,506 (24.8)
Malignant lymphoma4,649487 (10.5)
Multiple myeloma1,834170 (9.3)
Aplastic anemia388103 (26.5)
DIC1,76118 (1.0)
Purpura13012 (9.2)
Immunological disorders5210 (19.2)
AIDS10925 (22.9)
 Total for other blood and hematopoietic system diseases8,923825 (9.2)
Total14,9902,331 (15.6)
  • a These data were taken from references32, 33, 34, and 36. Among 78,981 patients with solid cancers, 1,359 patients suffered from mycoses. The mycosis rate for the solid-cancer patients was 1.7%. For blood and hematopoietic system diseases, 1,506 mycosis patients were among 6,067 leukemia and MDS patients (24.8%), and 825 patients, excluding leukemia and MDS patients, suffered from mycoses among 8,923 other patients with blood and hematopoietic system diseases (9.2%). In total, 15.6% of patients with blood and hematopoietic diseases suffered from mycoses.

  • b AML, acute myeloid leukemia; CML, chronic myeloid leukemia; ALL, acute lymphatic leukemia; CLL, chronic lymphatic leukemia; MoL, monocystic leukemia; ATL, adult T-cell leukemia; DIC, disseminated intravascular coagulation syndrome; Purpura, idiopathic thrombocytopenic purpura or thrombotic thrombocytopenic purpura.